GCAN explores strategic opportunities in AI and Quantum Computing

Greater Cannabis Company, Inc., a publicly traded biopharmaceutical company pioneering the development of next-generation therapeutics, announced that it has initiated a comprehensive process to explore strategic alternatives aimed at maximizing shareholder value. This strategic move underscores the Company's commitment to enhancing its market position and delivering robust returns to its investors. While GCANRx will continue to advance its existing biopharma lines of business, the exploration of strategic alternatives signifies a proactive approach to identifying opportunities that could propel the Company into new realms of growth and innovation.

Aitan Zacharin, Chief Executive Officer of GCANRx, commented on the development, stating, “There have been a number of companies focused on developing these cutting-edge technologies who have approached GCAN expressing interest in a potential merger. As part of our fiduciary obligation to our shareholders, we will explore these options thoroughly. Our goal is to ensure that any strategic decision we make aligns with our mission to deliver high-quality therapeutics and provides maximum value to our shareholders.” Zacharin emphasized that the burgeoning fields of quantum computing and artificial intelligence (AI) represent the next frontier in emerging technologies, rapidly evolving into multi-billion dollar industries. By considering mergers or strategic business combinations with leaders in these sectors, GCANRx aims to leverage advanced technologies to enhance its biopharmaceutical offerings and expand its research and development capabilities.

As part of the evaluation process, GCANRx will consider a range of strategic alternatives, including but not limited to a sale, merger, strategic business combination, or other transactions that could benefit the Company and its stakeholders. However, the Company has made it clear that it cannot assure shareholders that the exploration will result in a transaction or that any potential deal, if pursued, will be completed on attractive terms. Additionally, GCANRx has not established a specific timetable for the completion of this evaluation process. The Company remains committed to maintaining transparency and will provide further updates to shareholders in accordance with its ongoing disclosure obligations and applicable laws and regulations. This strategic initiative reflects GCANRx’s dedication to adapting to the dynamic biopharmaceutical landscape and positioning itself for sustained growth and success in the competitive market.